Involvement of spinal CC chemokine ligand 5 in the development of bone cancer pain in rats.

Abstract

In this study, we aimed to investigate the role of spinal CC chemokine ligand 5 (CCL5) in the development of bone cancer pain (BCP). A BCP model was established by inoculation of Walker 256 cells into the intramedullary space of rat tibia. The levels of spinal CCL5 mRNA and protein expression significantly and time dependently increased in BCP rats compared with sham rats. On day 15 after inoculation, intrathecal administration of anti-CCL5 neutralizing antibody (4 μg) significantly attenuated the established mechanical hyperalgesia in the Walker 256 cells-injected rats, and the effect was abolished by intrathecal pre-treatment with recombinant rat CCL5 (0.2 μg). These results suggest that the spinal CCL5 may be involved in the development of BCP. The findings of this study may provide an evidence for developing novel analgesic agents to treat BCP.

• Authors: Li-Hua Hang, Dong-Hua Shao, Zheng Chen, Yuan-Feng Chen, Wei-Wei Shu, Zhi-Guo Zhao
• Journal: Basic & clinical pharmacology & toxicology (Basic Clin Pharmacol Toxicol) Vol. 113 Issue 5 Pg. 325-8 (Nov 2013) ISSN: 1742-7843 [Electronic] England
• PMID: 23773283 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2013 Nordic Pharmacological Society. Published by John Wiley & Sons Ltd.

Chemical References

• Antibodies, Neutralizing
• Chemokine CCL5
• RNA, Messenger

Topics

• Animals
• Antibodies, Neutralizing (immunology)
• Bone Neoplasms (metabolism, pathology)
• Carcinoma 256, Walker (pathology)
• Chemokine CCL5 (genetics, immunology, metabolism)
• Disease Models, Animal
• Female
• Hyperalgesia (genetics, pathology)
• Injections, Spinal
• Pain (drug therapy, pathology)
• RNA, Messenger (metabolism)
• Rats
• Rats, Sprague-Dawley
• Tibia (metabolism, pathology)